Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study
2021 ◽
Vol 173
◽
pp. 108681
2008 ◽
Vol 101
(5)
◽
pp. 596-601
◽
Keyword(s):
1998 ◽
Vol 88
(6)
◽
pp. 913-917
◽
2017 ◽
Vol 31
(6)
◽
pp. 952-957
◽
Keyword(s):
1998 ◽
Vol 17
(3)
◽
pp. 263-269
◽